FGFR2 and intrahepatic cholangiocarcinoma: A Phase III trial is currently underway to assess the effectiveness and safety of futibatinib in comparison to gemcitabine-cisplatin chemotherapy as the initial therapeutic approach for individuals with advanced, metastatic, or recurrent unresectable ICC carrying a FGFR2 gene rearrangement [129].